| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 706 | 2020 |
| Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy D Cardinale, MT Sandri, A Martinoni, A Tricca LabTech, M Civelli, ... Journal of the American College of Cardiology 36 (2), 517-522, 2000 | 702 | 2000 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 679 | 2017 |
| Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels M Colleoni, A Rocca, MT Sandri, L Zorzino, G Masci, F Nole, G Peruzzotti, ... Annals of Oncology 13 (1), 73-80, 2002 | 592 | 2002 |
| Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ... The Lancet Oncology 15 (4), 396-405, 2014 | 422 | 2014 |
| Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy D Cardinale, MT Sandri, A Martinoni, E Borghini, M Civelli, G Lamantia, ... Annals of Oncology 13 (5), 710-715, 2002 | 391 | 2002 |
| Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients R Gennari, G Curigliano, N Rotmensz, C Robertson, M Colleoni, S Zurrida, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 338 | 2004 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 281 | 2020 |
| First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ... Journal of Clinical Oncology 30 (24), 3002-3011, 2012 | 277 | 2012 |
| Treatment of triple negative breast cancer (TNBC): current options and future perspectives M De Laurentiis, D Cianniello, R Caputo, B Stanzione, G Arpino, S Cinieri, ... Cancer treatment reviews 36, S80-S86, 2010 | 260 | 2010 |
| Angiogenic growth factors and endostatin in non‐Hodgkin's lymphoma F Bertolini, M Paolucci, F Peccatori, S Cinieri, A Agazzi, PF Ferrucci, ... British journal of haematology 106 (2), 504-509, 1999 | 220 | 1999 |
| Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program DL Pagano, C Girmenia, L Mele, P Ricci, ME Tosti, A Nosari, M Buelli, ... haematologica 86 (8), 862-870, 2001 | 214 | 2001 |
| Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase … S Pignata, D Lorusso, G Scambia, D Sambataro, S Tamberi, S Cinieri, ... The Lancet Oncology 16 (5), 561-568, 2015 | 176 | 2015 |
| Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer … M Tiseo, L Boni, F Ambrosio, A Camerini, E Baldini, S Cinieri, M Brighenti, ... Journal of Clinical Oncology 35 (12), 1281-1287, 2017 | 165 | 2017 |
| Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers F Bertolini, W Mingrone, A Alietti, PF Ferrucci, E Cocorocchio, F Peccatori, ... Annals of Oncology 12 (7), 987-990, 2001 | 153 | 2001 |
| Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial N Normanno, AM Rachiglio, M Lambiase, E Martinelli, F Fenizia, ... Annals of oncology 26 (8), 1710-1714, 2015 | 143 | 2015 |
| Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer L Orlando, A Cardillo, A Rocca, A Balduzzi, R Ghisini, G Peruzzotti, ... Anti-cancer drugs 17 (8), 961-967, 2006 | 142 | 2006 |
| Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial F Ciardiello, N Normanno, E Maiello, E Martinelli, T Troiani, S Pisconti, ... Annals of oncology 25 (9), 1756-1761, 2014 | 140 | 2014 |
| Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer P Fedele, A Marino, L Orlando, P Schiavone, A Nacci, F Sponziello, ... European journal of cancer 48 (1), 24-29, 2012 | 117 | 2012 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 116 | 2018 |
